Brief: Hansoh Pharmaceutical's Targeted Antibody Drug Conjugate Gets NMPA Breakthrough-Therapy-Designated-Drug
17/04/2025 15:57
April 17 (Reuters) - Hansoh Pharmaceutical Group Company Ltd 3692.HK: NMPA GRANTED BREAKTHROUGH-THERAPY-DESIGNATED-DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 Further company coverage: 3692.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion